Welcome to our dedicated page for Medical Care Technologies news (Ticker: MDCE), a resource for investors and traders seeking the latest updates and insights on Medical Care Technologies stock.
Medical Care Technologies Inc. develops and commercializes artificial intelligence applications across consumer software, imaging analysis, healthcare-oriented pre-screening and collectibles authentication. News about MDCE centers on its AI technology stack, including Snapshot Recipes, a mobile recipe application with AI-generated food and beverage content, and Real Game Used, a subsidiary developing a patent-pending AI authentication platform for sports memorabilia.
Company updates also cover AI imaging initiatives for dermatological analysis, wellness monitoring, product verification and automated quality control, as well as capital and asset-monetization activity through Infinite Auctions. Recurring announcements describe product redesigns, commercialization pathways, subsidiary activity, mobile-app user growth initiatives, and enterprise API or visual analytics use cases.
Medical Care Technologies (MDCE) has opened volunteer intake for the first human-submitted image cohort supporting its MDCE Melanoma Scan Beta testing initiative, following an earlier August 31, 2026 announcement.
The project moves beyond public cancer imaging datasets such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts by adding real-world user images. Volunteer images are expected to be used only for internal model evaluation, workflow and intake testing, body-map organization review, and longitudinal comparison functions. The company emphasizes that this is a development and testing process, not a clinical diagnosis program, and the beta platform has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent disease.
Medical Care Technologies (MDCE) is preparing the first custom enterprise demonstrations of its StrainScan Pro AI vision platform for agricultural clients. The software targets visual inspection, quality grading, consistency checks, and early issue detection across farming and post-harvest operations, optimized for portable use on iPad Air devices. The tailored demos are built around real operating conditions, such as produce inspection and crop-stress anomaly detection, to show how workflows can be adapted. The company emphasizes that these demonstrations are part of its enterprise development process and do not represent commercial contracts, while it continues to generate revenue through operating subsidiaries.
Medical Care Technologies (MDCE) highlighted ongoing development of its MDCE Melanoma Scan Beta, an AI-assisted imaging and body-map monitoring application designed to help users organize and compare visible skin images over time to support early awareness of potential melanoma warning signs.
The company frames the effort against 2026 American Cancer Society estimates of about 112,000 new invasive melanoma cases and 8,510 deaths in the United States, noting the large survival gap between localized and distant-stage disease. The beta-stage platform offers an interactive body-map interface for cataloging images, tracking changes across sessions, and flagging visuals for professional review. It has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent disease. Medical Care Technologies continues internal testing and volunteer image evaluations as it refines AI-assisted visual review and comparison functions.
Medical Care Technologies (OTCID:MDCE) announced that its proprietary AI vision platform, StrainScan Pro, is being advanced specifically for the multi-trillion-dollar agriculture and foodservice markets. The software supports visual quality analysis, consistency checks, and early quality-issue identification across farming, post-harvest handling, commercial kitchens, and high-volume food environments.
According to Medical Care Technologies, StrainScan Pro is designed for portable use on iPad Air devices, enabling field, packing-point, and in-kitchen deployment without fixed industrial systems. The company notes that global agricultural and foodservice markets together represent trillions of dollars in annual economic activity. StrainScan Pro is positioned as an enterprise visual analysis platform and is not a medical diagnostic device. Medical Care Technologies states it is continuing to advance AI vision solutions across high-value verticals while generating revenue through its operating subsidiaries.
Medical Care Technologies (OTCID: MDCE) announced that its MDCE Melanoma Scan Beta platform is entering a new phase of testing by seeking its first volunteer cohorts to provide human-submitted skin images. This follows earlier development based on public dermatology datasets such as HAM10000, ISIC Archive collections, and TCIA melanoma cohorts.
According to the company, real-world user images are intended to introduce variability in lighting, devices, distance, skin tone, and image quality to better assess intake, workflow, body-map organization, and AI model performance. The beta-stage application is designed for image organization and longitudinal tracking, has no regulatory clearance, and is not intended for diagnosis or treatment.
Medical Care Technologies (OTC PINK:MDCE) reported further development of longitudinal body-map monitoring capabilities in its MDCE Melanoma Scan Beta app. The AI-assisted platform is being designed to help users organize, catalog, and track visible skin images over time using structured, repeatable imaging workflows and an interactive body-map interface.
The company is refining workflow, image consistency, usability, platform infrastructure, and AI vision for temporal image analysis, within a multi-phase internal testing process. The beta platform remains in development, has no regulatory clearance, and is positioned as an image organization and monitoring system for preventative wellness awareness rather than for diagnosis or treatment.
Medical Care Technologies (OTCID:MDCE) highlighted the cross-industry versatility of its StrainScan Pro AI vision platform, which uses a single computer-vision architecture for both regulated retail environments and large-scale agriculture. The software supports visual quality verification for licensed retailers and agricultural tasks such as early pest, crop-stress, and quality detection.
According to Medical Care Technologies, StrainScan Pro is optimized for deployment on iPad Air devices, giving both sectors a uniform, portable enterprise solution while allowing the company to advance one proprietary system. The company develops and commercializes AI vision software and does not handle cultivation or sale of plant products.
Medical Care Technologies (OTC PINK:MDCE) highlighted the enterprise-ready design of its StrainScan Pro AI vision platform, which uses a proprietary architecture optimized for rapid, straightforward deployment across multi-location retail and agricultural operations on iPad Air devices.
According to Medical Care Technologies, this tablet-based approach is intended to lower adoption barriers versus fixed industrial systems by standardizing the same software across fields, packing facilities, distribution environments, and retail sites. The company emphasized that it develops and commercializes AI vision software but does not cultivate, process, distribute, or sell cannabis or any plant products, and continues to generate revenue through operating subsidiaries.
Medical Care Technologies (OTC PINK: MDCE) reported further technical progress on its StrainScan Pro AI vision platform, emphasizing continuously learning computer-vision models designed to improve visual accuracy over time in both agricultural and regulated retail environments.
According to the company, StrainScan Pro refines performance as it processes more real-world visual data, enhancing identification of strain and quality characteristics for licensed operators and supporting detection of pests, crop stress, and quality indicators in agricultural settings. The software is optimized for deployment on iPad Air devices, preserving a portable enterprise form factor while the underlying AI models evolve. Medical Care Technologies stated that it develops and commercializes AI vision software, does not handle plant products, and is advancing AI capabilities across high-value verticals while generating revenue through operating subsidiaries.
Medical Care Technologies (OTC: MDCE) highlighted its StrainScan Pro platform as a scalable, enterprise AI vision solution for multi-location retail and agricultural operators. The proprietary software, optimized for deployment on iPad Air devices, supports visual strain and quality verification for licensed retail operators, early detection of pests and crop illness in the field, and freshness tracking concepts from harvest through distribution.
The company emphasized that it develops and commercializes AI vision software and does not handle cultivation or sale of plant products. StrainScan Pro targets multi-billion-dollar retail sectors and the global agriculture market, aligning with Medical Care Technologies’ broader AI vision strategy across high-value verticals.